Analgesics Market by Type (Non-opioids and Opioids) and by Route of Administration (Oral, Intravenous, Rectal, Transdermal, and Topical) – Global Opportunity Analysis and Industry Forecast 2022–2030

Analgesics Market

Industry:  Life Sciences & Healthcare | Publish Date: Jan 2023 | No of Pages:  246 | No. Tables:  136 | No. Figures:  106

Market Overview:

The analgesics market size was valued at USD 35.03 million in 2021 and is expected to reach USD 56.86 million by 2030, at a CAGR of 4.90% during the forecast period 2022–2030.

The term ‘analgesics’ refers to a class of drugs that are designed to relieve pain without causing the loss of consciousness. These medicines are used as pain-relieving agents to reduce different types of pain such as headaches and arthritis.

Increasing chronic and infectious diseases among people

The increasing prevalence of chronic diseases such as heart diseases, stroke, chronic obstructive pulmonary disease, asthma, and diabetes are causing untimely deaths in nations with low to medium incomes. According to the WHO, in 2021, various types of chronic diseases such as cardiovascular diseases, cancer, respiratory diseases, and diabetes are responsible for approximately 17.9 million, 9.3 million, 4.1 million, and 1.5 million deaths, respectively.

In addition, there has been a significant increase in the number of people suffering from infectious diseases such as gastrointestinal, respiratory, and neurology. A surge in the prevalence of these medical conditions increases the demand for painkillers, which in turn is driving the analgesics market growth.

Rising number of medical surgeries across the world

Factors such as the surging demand for exact and appropriate laparoscopic medical procedures, rising need for surgeries for the geriatric population, and growing instances of injury wounds have all contributed to the increased use of analgesics. Analgesia forms a crucial part of the perioperative management of patients undergoing open abdominal surgery. It is now well-established that optimal pain management not only facilitates patient well-being but also enhances recovery after surgery.

The use of conventional modalities including central neuraxial blockade and opioids cannot be extended to patients undergoing fast-track surgery. Hence, an aggressive perioperative analgesic regimen/protocol is required for effective pain relief, with minimal side effects and which could be managed easily by the patient or the relatives at home away from the hospital setting.

Changing regulatory landscape in the medical drugs industry restrains the market growth

Medical device manufacturers are facing an exceptionally unpredictable regulatory environment. From 2005 to 2010, the average time taken to approve a 510 (k) application increased by 43%. Further, the time required to obtain a premarket approval increased by 75%. The US Food and Drug Administration (FDA) mandated that surgeons carry out operations with the utmost clinical care and with the utmost effectiveness of the surgical product.

It also increases the risk of product, especially when companies lack the funds to conduct additional studies to support additional data requirements from the FDA. These delays in approvals along with regulatory reforms regarding use of analgesics also restrain the growth of the analgesics market.

Strategic collaborations and advancements in medical drug development creates new opportunities

Companies in the analgesics industry are increasingly turning to acquisition as a growth strategy. In order to gain a competitive advantage and fortify their foothold in the industry, major analgesics medicine manufacturers are buying smaller businesses. These purchases enable businesses in expanding regionally and gaining specialized expertise in new product research and development.

Advances in the field of molecular neurobiology have created a continual flow of potential targets. Phenotyping of transgenic mice in pain and inflammation checks can provide early target validation, although adoption of such targets is a high-risk strategy. Identifying receptor or ion channel targets that show phenotypic changes related to the pathophysiology of human pain could provide treatments of pain syndromes that are refractory to existing analgesics that create ample growth opportunities for the market players in the upcoming years.

North America currently dominates the analgesics industry

North America holds the lion’s share of analgesics market at present and is expected to boost the growth of the market during the forecast period. This can be attributed to the rising geriatric population suffering from joint pain that has increased the demand for pain treatment therapies. These therapies employ different types of analgesics that further drives the market growth in this region. Moreover, the prevalence of osteoarthritis, cardiovascular diseases, and cancer are on the rise in the region, which has also increased the demand for analgesics.

Asia-Pacific region witnessed substantial growth in the global analgesics market

The Asia-Pacific region is expected to show a steady rise in the analgesics market; this can be attributed to the increasing prevalence of arthritis, several other bone-related conditions, and diabetic neuropathy, leading to pain. In addition, fever is becoming more prevalent, resulting in an increase in the use of paracetamol, which in turn drives the growth of the analgesics market.

Competitive Landscape

The analgesics market share comprises several market players such as Abbott Laboratories, Bayer AG, Glaxosmithkline plc, Johnson and Johnson, Pfizer Inc, Novartis AG, Teva Pharmaceuticals, Sanofi SA, ABBVIE INC, and Sun Pharma. These market players have adopted various strategies such as acquisitions and product launches to strengthen their footprint in the market.

For instance, in May 2022, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. This acquisition was done for the production of NURTEC ODT for acute treatment and episodic prevention of migraine in adults. Further, in September 2021, Novartis announced that the US Food and Drug Administration (FDA) had granted fast-track designation for LNA043 for the treatment of osteoarthritis of the knee. LNA043 was developed as a potential first in class disease modifying treatment for osteoarthritis (OA).

KEY MARKET SEGMENTS

By Type

  • Non-opioids

  • Opioids

By Route of Administration

  • Oral

  • Intravenous

  • Rectal

  • Transdermal

  • Topical

By Region

  • North America

    • US

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Spain

    • Sweden

    • Russia

    • Denmark

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • Indonesia

    • Rest of Asia-Pacific

  • RoW

    • UAE

    • Saudi Arabia

    • Brazil

    • Venezuela

    • Kenya

    • Morocco

    • Nigeria

    • Chile

    • Remaining Countries

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Analysis Period

2019–2030

Base Year Considered

2020

Forecast Period

2020–2030

Market Size Estimation

Billion (USD)

Market Segmentation

By Type (Non-opioids and Opioids) and by Route of Administration (Oral, Intravenous, Rectal, Transdermal, and Topical)

Geographical Segmentation

North America (U.S., Canada, Mexico) Europe (UK, Germany, Sweden, Russia, Denmark, France, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Indonesia, Australia, Rest of APAC), Rest of the World (UAE, Saudi Arabia, Brazil, Venezuela, Kenya, Morocco, Nigeria, Chile, Remaining Countries)

Companies Profiled

Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi.

column chart pie chart

TABLE OF CONTENT

1. INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. WHO SHOULD READ THIS REPORT 

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1        SECONDARY RESEARCH

1.4.2        DATA ANALYSIS FRAMEWORK

1.4.3        MARKET SIZE ESTIMATION

1.4.4        FORECASTING

1.4.5        PRIMARY RESEARCH AND DATA VALIDATION

2. ANALGESICS MARKET – EXECUTIVE SUMMARY

2.1. MARKET SNAPSHOT, 2021 - 2030, MILLION USD

3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. MARKET DYNAMICS

3.2.1        DRIVERS

3.2.1.1. INCREASING CHRONIC AND INFECTIOUS DISEASES AMONG PEOPLE

3.2.1.2. INCREASING NUMBER OF MEDICAL SURGERIES ACROSS THE WORLD

3.2.1.3. ELEVATING AWARENESS ABOUT PALLIATIVE CARE AND PAIN MANAGEMENT

3.2.2        RESTRAINTS

3.2.2.1. CHANGING REGULATORY LANDSCAPE IN THE MEDICAL DRUGS INDUSTRY

3.2.3        OPPORTUNITIES

3.2.3.1. INCREASING NUMBER OF STRATEGIC COLLABORATIONS AND ADVANCEMENTS IN MEDICAL DRUG DEVELOPMENT

4. GLOBAL ANALGESICS MARKET, BY TYPE

4.1. OVERVIEW

4.2. NON-OPIOID

4.2.1        NON-OPIOID MARKET, BY REGION

4.3. OPIOIDS

4.3.1        OPIOIDS MARKET, BY REGION

5. GLOBAL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

5.1. OVERVIEW

5.2. ORAL ROUTE

5.2.1        ORAL ROUTE MARKET, BY REGION

5.3. INTRAVENOUS ROUTE

5.3.1        INTRAVENOUS ROUTE MARKET, BY REGION

5.4. RECTAL ROUTE

5.4.1        RECTAL ROUTE MARKET, BY REGION

5.5. TRANSDERMAL ROUTE

5.5.1        TRANSDERMAL ROUTE MARKET, BY REGION

5.6. TOPICAL ROUTE

5.6.1        TOPICAL ROUTE MARKET, BY REGION

6. GLOBAL ANALGESICS BY REGION

6.1. OVERVIEW

6.2. NORTH AMERICA

6.2.1        NORTH AMERICA ANALGESICS MARKET, BY TYPE

6.2.2        NORTH AMERICA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.2.3        NORTH AMERICA ANALGESICS, BY COUNTRY

6.2.3.1. U.S.

6.2.3.1.1. U.S. ANALGESICS MARKET, BY TYPE

6.2.3.1.2. U.S. ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.2.3.2. CANADA

6.2.3.2.1. CANADA ANALGESICS MARKET, BY TYPE

6.2.3.2.2. CANADA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.2.3.3. MEXICO

6.2.3.3.1. MEXICO ANALGESICS MARKET, BY TYPE

6.2.3.3.2. MEXICO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3. EUROPE

6.3.1        EUROPE ANALGESICS MARKET, BY TYPE

6.3.2        EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3        EUROPE ANALGESICS, BY COUNTRY

6.3.3.1. UK

6.3.3.1.1. UK ANALGESICS MARKET, BY TYPE

6.3.3.1.2. UK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.2. GERMANY

6.3.3.2.1. GERMANY ANALGESICS MARKET, BY TYPE

6.3.3.2.2. GERMANY ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.3. SPAIN

6.3.3.3.1. SPAIN ANALGESICS MARKET, BY TYPE

6.3.3.3.2. SPAIN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.4. SWEDEN

6.3.3.4.1. SWEDEN ANALGESICS MARKET, BY TYPE

6.3.3.4.2. SWEDEN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.5. FRANCE

6.3.3.5.1. FRANCE ANALGESICS MARKET, BY TYPE

6.3.3.5.2. FRANCE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.6. RUSSIA

6.3.3.6.1. RUSSIA ANALGESICS MARKET, BY TYPE

6.3.3.6.2. RUSSIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.7. DENMARK

6.3.3.7.1. DENMARK ANALGESICS MARKET, BY TYPE

6.3.3.7.2. DENMARK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.3.3.8. REST OF EUROPE

6.3.3.8.1. REST OF EUROPE ANALGESICS MARKET, BY TYPE

6.3.3.8.2. REST OF EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4. ASIA-PACIFIC

6.4.1        ASIA-PACIFIC ANALGESICS MARKET, BY TYPE

6.4.2        ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3        ASIA-PACIFIC ANALGESICS, BY COUNTRY

6.4.3.1. JAPAN

6.4.3.1.1. JAPAN ANALGESICS MARKET, BY TYPE

6.4.3.1.2. JAPAN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3.2. CHINA

6.4.3.2.1. CHINA ANALGESICS MARKET, BY TYPE

6.4.3.2.2. CHINA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3.3. INDIA

6.4.3.3.1. INDIA ANALGESICS MARKET, BY TYPE

6.4.3.3.2. INDIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3.4. AUSTRALIA

6.4.3.4.1. AUSTRALIA ANALGESICS MARKET, BY TYPE

6.4.3.4.2. AUSTRALIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3.5. INDONESIA

6.4.3.5.1. INDONESIA ANALGESICS MARKET, BY TYPE

6.4.3.5.2. INDONESIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.4.3.6. REST OF ASIA-PACIFIC

6.4.3.6.1. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY TYPE

6.4.3.6.2. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5. REST OF WORLD

6.5.1        REST OF WORLD ANALGESICS MARKET, BY TYPE

6.5.2        REST OF WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3        REST OF WORLD ANALGESICS, BY COUNTRY

6.5.3.1. BRAZIL

6.5.3.1.1. BRAZIL ANALGESICS MARKET, BY TYPE

6.5.3.1.2. BRAZIL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.2. VENEZUELA

6.5.3.2.1. VENEZUELA ANALGESICS MARKET, BY TYPE

6.5.3.2.2. VENEZUELA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.3. CHILE

6.5.3.3.1. CHILE ANALGESICS MARKET, BY TYPE

6.5.3.3.2. CHILE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.4. KINGDOM OF SAUDI ARABIA (KSA)

6.5.3.4.1. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY TYPE

6.5.3.4.2. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.5. UAE

6.5.3.5.1. UAE ANALGESICS MARKET, BY TYPE

6.5.3.5.2. UAE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.6. MOROCCO

6.5.3.6.1. MOROCCO ANALGESICS MARKET, BY TYPE

6.5.3.6.2. MOROCCO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.7. KENYA

6.5.3.7.1. KENYA ANALGESICS MARKET, BY TYPE

6.5.3.7.2. KENYA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.8. NIGERIA

6.5.3.8.1. NIGERIA ANALGESICS MARKET, BY TYPE

6.5.3.8.2. NIGERIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

6.5.3.9. REMAINING COUNTRIES

6.5.3.9.1. REMAINING COUNTRIES ANALGESICS MARKET, BY TYPE

6.5.3.9.2. REMAINING COUNTRIES ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

7. COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1        COMPANY OVERVIEW

7.1.2        COMPANY SNAPSHOT

7.1.3        OPERATING BUSINESS SEGMENTS

7.1.4        PRODUCT PORTFOLIO

7.1.5        BUSINESS PERFORMANCE

7.1.6        SALES BY BUSINESS SEGMENT

7.1.7        SALES BY GEOGRAPHIC SEGMENT

7.1.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.1.9        PRIMARY MARKET COMPETITORS

7.2. BAYER AG

7.2.1        COMPANY OVERVIEW

7.2.2        COMPANY SNAPSHOT

7.2.3        OPERATING BUSINESS SEGMENTS

7.2.4        PRODUCT PORTFOLIO

7.2.5        BUSINESS PERFORMANCE

7.2.6        SALES BY BUSINESS SEGMENT

7.2.7        SALES BY GEOGRAPHIC SEGMENT

7.2.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.2.9        PRIMARY MARKET COMPETITORS

7.3. GLAXOSMITHKLINE PLC

7.3.1        COMPANY OVERVIEW

7.3.2        COMPANY SNAPSHOT

7.3.3        OPERATING BUSINESS SEGMENTS

7.3.4        PRODUCT PORTFOLIO

7.3.5        BUSINESS PERFORMANCE

7.3.6        SALES BY BUSINESS SEGMENT

7.3.7        SALES BY GEOGRAPHIC SEGMENT

7.3.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.3.9        PRIMARY MARKET COMPETITORS

7.4. JOHNSON & JOHNSON

7.4.1        COMPANY OVERVIEW

7.4.2        COMPANY SNAPSHOT

7.4.3        OPERATING BUSINESS SEGMENTS

7.4.4        PRODUCT PORTFOLIO

7.4.5        BUSINESS PERFORMANCE

7.4.6        SALES BY BUSINESS SEGMENT

7.4.7        SALES BY GEOGRAPHIC SEGMENT

7.4.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.4.9        PRIMARY MARKET COMPETITORS

7.5. NOVARTIS AG

7.5.1        COMPANY OVERVIEW

7.5.2        COMPANY SNAPSHOT

7.5.3        OPERATING BUSINESS SEGMENTS

7.5.4        PRODUCT PORTFOLIO

7.5.5        BUSINESS PERFORMANCE

7.5.6        SALES BY BUSINESS SEGMENT

7.5.7        SALES BY GEOGRAPHIC SEGMENT

7.5.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.5.9        PRIMARY MARKET COMPETITORS

7.6. PFIZER INC

7.6.1        COMPANY OVERVIEW

7.6.2        COMPANY SNAPSHOT

7.6.3        OPERATING BUSINESS SEGMENTS

7.6.4        PRODUCT PORTFOLIO

7.6.5        BUSINESS PERFORMANCE

7.6.6        SALES BY GEOGRAPHIC SEGMENT

7.6.7        SALES BY GEOGRAPHIC SEGMENT

7.6.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.6.9        PRIMARY MARKET COMPETITORS

7.7. SANOFI SA

7.7.1        COMPANY OVERVIEW

7.7.2        COMPANY SNAPSHOT

7.7.3        OPERATING BUSINESS SEGMENTS

7.7.4        PRODUCT PORTFOLIO

7.7.5        BUSINESS PERFORMANCE

7.7.6        SALES BY BUSINESS SEGMENT

7.7.7        SALES BY GEOGRAPHIC SEGMENT

7.7.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.7.9        PRIMARY MARKET COMPETITORS

7.8. TEVA PHARMACEUTICALS

7.8.1        COMPANY OVERVIEW

7.8.2        COMPANY SNAPSHOT

7.8.3        PRODUCT PORTFOLIO

7.8.4        BUSINESS PERFORMANCE

7.8.5        SALES BY GEOGRAPHIC SEGMENT

7.8.6        KEY STRATEGIC MOVES & DEVELOPMENTS

7.8.7        PRIMARY MARKET COMPETITORS

7.9. ABBVIE INC

7.9.1        COMPANY OVERVIEW

7.9.2        COMPANY SNAPSHOT

7.9.3        OPERATING BUSINESS SEGMENTS

7.9.4        PRODUCT PORTFOLIO

7.9.5        BUSINESS PERFORMANCE

7.9.6        SALES BY BUSINESS SEGMENT

7.9.7        SALES BY GEOGRAPHIC SEGMENT

7.9.8        KEY STRATEGIC MOVES & DEVELOPMENTS

7.9.9        PRIMARY MARKET COMPETITORS

7.10.   SUN PHARMA

7.10.1     COMPANY OVERVIEW

7.10.2     COMPANY SNAPSHOT

7.10.3     PRODUCT PORTFOLIO

7.10.4     BUSINESS PERFORMANCE

7.10.5     SALES BY GEOGRAPHIC SEGMENT

7.10.6     KEY STRATEGIC MOVES & DEVELOPMENTS

7.10.7     PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. GLOBAL ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 2. NON-OPIOID MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 3. OPIOIDS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 4. GLOBAL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 5. ORAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 6. INTRAVENOUS ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 7. RECTAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 8. TRANSDERMAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 9. TOPICAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 10. GLOBAL ANALGESICS BY REGION, 2021-2030, MILLION USD

TABLE 11. NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 12. NORTH AMERICA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 13. NORTH AMERICA ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

TABLE 14. U.S. ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 15. U.S. ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 16. CANADA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 17. CANADA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 18. MEXICO ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 19. MEXICO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 20. EUROPE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 21. EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 22. EUROPE ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

TABLE 23. UK ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 24. UK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 25. GERMANY ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 26. GERMANY ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 27. SPAIN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 28. SPAIN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 29. SWEDEN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 30. SWEDEN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 31. FRANCE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 32. FRANCE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 33. RUSSIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 34. RUSSIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 35. DENMARK ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 36. DENMARK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 37. REST OF EUROPE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 38. REST OF EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 39. ASIA-PACIFIC ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 40. ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 41. ASIA-PACIFIC ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

TABLE 42. JAPAN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 43. JAPAN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 44. CHINA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 45. CHINA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 46. INDIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 47. INDIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 48. AUSTRALIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 49. AUSTRALIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 50. INDONESIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 51. INDONESIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 52. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 53. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 54. REST OF WORLD ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 55. REST OF WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 56. REST OF WORLD ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

TABLE 57. BRAZIL ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 58. BRAZIL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 59. VENEZUELA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 60. VENEZUELA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 61. CHILE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 62. CHILE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 63. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 64. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 65. UAE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 66. UAE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 67. MOROCCO ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 68. MOROCCO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 69. KENYA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 70. KENYA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 71. NIGERIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 72. NIGERIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 73. REMAINING COUNTRIES ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 74. REMAINING COUNTRIES ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 75. ABOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 76. ABOTT LABORATORIES: OPERATING SEGMENTS

TABLE 77. ABOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 78. ABOTT LABORATORIES: BUSINESS SEGMENT

TABLE 79. ABOTT LABORATORIES: GEOGRAPHIC SEGMENT

TABLE 80. ABOTT LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 81. BAYER AG: COMPANY SNAPSHOT

TABLE 82. BAYER AG: OPERATING SEGMENTS

TABLE 83. BAYER AG: PRODUCT PORTFOLIO

TABLE 84. BAYER AG: BUSINESS SEGMENT

TABLE 85. BAYER AG: GEOGRAPHIC SEGMENT

TABLE 86. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 87. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 88. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 89. GLAXOSMITHKLINE PLC: BUSINESS SEGMENT

TABLE 90. GLAXOSMITHKLINE PLC: GEOGRAPHIC SEGMENT

TABLE 91. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES & DEVELOPMENT

TABLE 92. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 93. JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 94. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 95. JOHNSON & JOHNSON: BUSINESS SEGMENT

TABLE 96. JOHNSON & JOHNSON: GEOGRAPHIC SEGMENT

TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 98. NOVARTIS AG: OPERATING SEGMENTS

TABLE 99. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 100. NOVARTIS AG: BUSINESS SEGMENT

TABLE 101. NOVARTIS AG: GEOGRAPHIC SEGMENT

TABLE 102. NOVARTIS AG: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 103. PFIZER INC: COMPANY SNAPSHOT

TABLE 104. PFIZER INC.: OPERATING SEGMENTS

TABLE 105. PFIZER INC: PRODUCT PORTFOLIO

TABLE 106. PFIZER INC: BUSINESS SEGMENT

TABLE 107. PFIZER INC: GEOGRAPHIC SEGMENT

TABLE 108. PFIZER INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 109. SANOFI SA: COMPANY SNAPSHOT

TABLE 110. SANOFI SA: OPERATING SEGMENTS

TABLE 111. SANOFI SA: PRODUCT PORTFOLIO

TABLE 112. SANOFI SA: BUSINESS SEGMENT

TABLE 113. SANOFI SA: GEOGRAPHIC SEGMENT

TABLE 114. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 115. TEVA PHARMACEUTICAL: PRODUCT PORTFOLIO

TABLE 116. TEVA PHARMACEUTICAL: GEOGRAPHIC SEGMENT

TABLE 117. ABBVIE INC: COMPANY SNAPSHOT

TABLE 118. ABBVIE INC: OPERATING SEGMENTS

TABLE 119. ABBVIE INC: PRODUCT PORTFOLIO

TABLE 120. ABBVIE INC: BUSINESS SEGMENT

TABLE 121. ABBVIE INC: GEOGRAPHIC SEGMENT

TABLE 122. ABBVIE INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 123. SUN PHARMA: COMPANY SNAPSHOT

TABLE 124. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 125. SUN PHARMA: GEOGRAPHIC SEGMENT

TABLE 126. SUN PHARMA: KEY STRATEGIC MOVES & DEVELOPMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 2. NON-OPIOID MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 3. OPIOIDS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 4. GLOBAL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 5. ORAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 6. INTRAVENOUS ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 7. RECTAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 8. TRANSDERMAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 9. TOPICAL ROUTE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 10. GLOBAL ANALGESICS BY REGION, 2021-2030, MILLION USD

FIGURE 11. NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 12. NORTH AMERICA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 13. NORTH AMERICA ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 14. U.S. ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 15. U.S. ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 16. CANADA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 17. CANADA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 18. MEXICO ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 19. MEXICO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 20. EUROPE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 21. EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 22. EUROPE ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 23. UK ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 24. UK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 25. GERMANY ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 26. GERMANY ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 27. SPAIN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 28. SPAIN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 29. SWEDEN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 30. SWEDEN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 31. FRANCE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 32. FRANCE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 33. RUSSIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 34. RUSSIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 35. DENMARK ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 36. DENMARK ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 37. REST OF EUROPE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 38. REST OF EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 39. ASIA-PACIFIC ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 40. ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 41. ASIA-PACIFIC ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 42. JAPAN ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 43. JAPAN ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 44. CHINA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 45. CHINA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 46. INDIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 47. INDIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 48. AUSTRALIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 49. AUSTRALIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 50. INDONESIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 51. INDONESIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 52. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 53. REST OF ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 54. REST OF WORLD ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 55. REST OF WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 56. REST OF WORLD ANALGESICS, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 57. BRAZIL ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 58. BRAZIL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 59. VENEZUELA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 60. VENEZUELA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 61. CHILE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 62. CHILE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 63. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 64. KINGDOM OF SAUDI ARABIA (KSA) ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 65. UAE ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 66. UAE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 67. MOROCCO ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 68. MOROCCO ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 69. KENYA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 70. KENYA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 71. NIGERIA ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 72. NIGERIA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 73. REMAINING COUNTRIES ANALGESICS MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 74. REMAINING COUNTRIES ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 75. ABOTT LABORATORIES: NET SALES, 2019–2021 ($MILLION)

FIGURE 76. ABOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 77. BAYER AG: NET SALES, 2019–2021 ($MILLION)

FIGURE 78. BAYER AG: PRIMARY MARKET COMPETITORS

FIGURE 79. GLAXOSMITHKLINE PLC: NET SALES, 2019–2021 ($MILLION)

FIGURE 80. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS

FIGURE 81. JOHNSON & JOHNSON, 2019–2021 ($MILLION)

FIGURE 82. JOHNSON & JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 83. NOVARTIS AG: NET SALES, 2019–2021 ($MILLION)

FIGURE 84. NOVARTIS AG: PRIMARY MARKET COMPETITORS

FIGURE 85. PFIZER INC: NET SALES, 2019–2021 ($MILLION)

FIGURE 86. PFIZER INC: PRIMARY MARKET COMPETITORS

FIGURE 87. SANOFI SA: NET SALES, 2019–2021 ($MILLION)

FIGURE 88. SANOFI SA: PRIMARY MARKET COMPETITORS

FIGURE 89. TEVA PHARMACEUTICALS: NET SALES, 2019–2021 ($MILLION)

FIGURE 90. TEVA PHARMACEUTICALS: PRIMARY MARKET COMPETITORS

FIGURE 91. ABBVIE INC: NET SALES, 2019–2021 ($MILLION)

FIGURE 92. ABBVIE INC: PRIMARY MARKET COMPETITORS

FIGURE 93. SUN PHARMA: NET SALES, 2019–2021 ($MILLION)

FIGURE 94. SUN PHARMA: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Bayer AG
  • Novartis AG
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Johnson & Johnson
  • Reckitt Benckiser (RB)
  • Endo Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Sanofi

Frequently Asked Questions
What will be the worth of global Analgesics market by the end of 2030?

According to the report published by Next Move Strategy Consulting, the Analgesics market business is expected to hit at $29.58 billion (USD) by 2030.

Which region is expected to hold the highest market share in the Analgesics Market?

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Which are the top companies in the Analgesics industry?

Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi.

What are the market segmentations and scope of the study?

The global Analgesics market share analysis is based on type, route of administration and geography.

How big is the Analgesics market?

Currently (in 2019), the market value stands at USD 25.44 billion and it is anticipated to reach USD 29.58 billion by 2030.